A South Korean court ruled this week that penalties imposed against Samsung BioLogics, parent company of biosimilar developer Samsung Bioepis, by the Financial Services Commission (FSC) for allegedly committing fraud have been suspended.
A South Korean court ruled this week that penalties imposed against Samsung BioLogics, parent company of biosimilar developer Samsung Bioepis, by the Financial Services Commission (FSC) for allegedly committing fraud have been suspended.
In November, the Nikkei Asian Review reported that the FSC had found that, in 2015, Samsung BioLogics had used accounting methods that allegedly inflated the value of the company prior to an initial public offering in 2016.
The FSC imposed penalties including an estimated $7.05 million fine, suspended Samsung BioLogics’ stock trading, and called for the firing of the firm’s chief executive officer, Kim Tae-han, as well as the chief financial officer.
The company’s stock subsequently resumed trading in December 2018 after the exchange ruled that the company’s shares could remain listed while the case played out.
Upon the alleged fraud being made public, Samsung Biologics sent a letter to its shareholders apologizing for any confusion caused by the “recent accounting issue,” and went on to say that the “[Securities and Futures Commission]’s announcement is very unfortunate as it is our firm belief that Samsung BioLogics has not breached any accounting rules at all.”
In fact, the company indicated that it had sought the advice of multiple accounting firms, all of whom deemed its accounting practices acceptable. The auditors who advised Samsung BioLogics were also sanctioned by the commission by way of fines and barring the agencies from auditing Samsung BioLogics for up to 5 years.
Samsung BioLogics then filed an administrative lawsuit at the Seoul Administrative Court seeking to nullify the commission’s findings as well as calling for an injunction to stop any disciplinary action until the court rules on the case.
“The court concluded that an immediate sanction on the company could lead to irreparable damage when its violation of accounting standards has yet to be proven in court,” said an unidentified court official, according to Reuters.
The FSC has stated that it will review the details of the courts findings and plan whether to file an immediate appeal. Samsung BioLogics, for its part, has maintained its innocence. “The court’s decision is fortunate. We will do our best to prove the legitimacy of the company’s handling of accounting,” said a Samsung BioLogics official.
Samsung now awaits the outcome of the prosecutors’ investigation.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.